TB Alliance announced partnership with Hongqi Pharma to commercialize therapy for d Drug-resistant TB in China

On Jan. 17, 2020, the Non-profit drug developer TB Alliance granted Shenyang Hongqi Pharmaceuticals , a subsidiary of Shanghai Fosun Pharmaceutical a license to market the anti-TB medicine pretomanid as part of the three-drug ﾓBPaLﾔ regimen.

Hongqi Pharma agreed to commercialize the anti-tuberculosis medicine in the Peopleﾒs Republic of China.

Tags:

,

Source: Fosun Pharma
Credit:

Visit News/History Source
Transfection Has Never Been So Easy With Avalanche® Transfection Reagents for Cancer Cells, Primary Cells, And Other Difficult-To-Transfect Cells.Primary Cells, And Other Difficult-To-Transfect Cells.